Likang gets trial ok for China’s first personalized cancer vaccine
Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted…
March 17, 2023 - 3 minutes
Vaccines
Beyond Biotech podcast 37: Natural killer cells, biopharma revenue, toxic shock syndrome vaccine
This week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway;…
March 9, 2023 - 3 minutes
AELIX announces ‘important step towards HIV eradication’
AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies…
February 24, 2023 - 4 minutes
Immuno Cure starts HIV drug trial
Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park,…
February 17, 2023 - 3 minutes
Scancell looking to partner after positive COVID vaccine data
Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease,…
February 14, 2023 - 5 minutes
First toxic shock syndrome vaccine phase 2 study completed
The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a…
February 9, 2023 - 4 minutes
Cleveland Clinic breast cancer vaccine study moves forward
Researchers from global health system Cleveland Clinic have launched the next step in their novel…
February 9, 2023 - 3 minutes
AAHI bags $9.9M to develop nasal spray influenza RNA vaccine
The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up…
February 7, 2023 - 3 minutes
Watch: pHion Therapeutics talks about next-generation mRNA vaccines
pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic…
January 23, 2023 - 1 minute
Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design
A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness…
January 12, 2023 - 3 minutes
ErVaccine raises €4.5M to start therapeutic cancer vaccine trial
ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive…
January 9, 2023 - 3 minutes
Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine
Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine…
December 21, 2022 - 3 minutes
